Mp0533 (Multispecific Darpin Cd3 Engager Targeting Cd33, Cd123 And Cd70) Monotherapy, Part 1, Mp0533 (Multispecific Darpin Cd3 Engager Targeting Cd33, Cd123 And Cd70) Monotherapy, Part 2-Arm A, Mp0533 (Multispecific Darpin Cd3 Engager Targeting Cd33, Cd123 And Cd70) + Azacitidine + Venetoclax, Mp0533 With Obinutuzumab Pretreatment, Mp0533 + Azacitidine + Venetoclax With Optional Obinutuzumab Pretreatment, Arm B Relapsed/Refractory Aml, Mp0533 + Azacitidine + Venetoclax With Optional Obinutuzumab Pretreatment, Arm B In Treatment Naïve Patients
Newly Diagnosed, Leukemia, Myeloid, Acute
Phase I/II
Recruiting
Study of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic Syndrome
Dec 14, 2022
―
Mp0317, A Tri-Specific Fibroblast Activation Protein (Fap) X Cd40 Darpin® Drug Candidate (Q3w Regimen), Mp0317, A Tri-Specific Fibroblast Activation Protein (Fap) X Cd40 Darpin® Drug Candidate (Q1w Regimen)
Advanced Malignant Solid Tumor
Phase I
Terminated
First-in-human Safety and Tolerability of MP0317 in Patients With Relapsed/Refractory Advanced Solid Tumors
Sep 30, 2021
―
Ensovibep
Covid-19
Phase I
Terminated
Safety, Tolerability and PK of Ensovibep (MP0420 - a New Candidate With Potential for Treatment of COVID-19)
Apr 28, 2021
―
Ensovibep
COVID19
Phase II
Completed
Viral Clearance, PK and Tolerability of Ensovibep in COVID-19 Patients
Apr 06, 2021
―
Ensovibep
Covid-19
Phase II/III
Terminated
A Dose Finding, Efficacy and Safety Study of Ensovibep (MP0420) in Ambulatory Adult Patients With Symptomatic COVID-19
Mar 24, 2021
―
Mp0310
Advanced Solid Tumor
Phase I
Completed
Study to Investigate the Safety, Blood Levels and Activity of MP0310 in Patients With Advanced Solid Tumors
Aug 05, 2019
―
Mp0250 Darpin® Drug Candidate, Osimertinib
Egfr-Mutated Nsclc (Disorder)
Phase I
Terminated
MP0250 DARPin® Protein Plus Osimertinib in Patients With EGFR-mutated NSCLC
Jan 10, 2018
―
Mp0250 Plus Bor+Dex
Multiple Myeloma In Relapse
Phase I/II
Completed
A Phase 2 Trial of MP0250 Plus Bortezomib + Dexamethasone in Patients With Multiple Myeloma
Apr 18, 2017
―
Mp0274
Neoplasms
Phase I
Completed
First-in-human Study to Investigate Safety, Blood Levels and Activity of MP0274 in Cancer Patients With HER2-positive Solid Tumors
Mar 06, 2017
―
Mp0250
Neoplasms
Phase I/II
Completed
First-in-human Study to Investigate the Safety, Tolerability and Blood Levels of the Test Drug MP0250 in Cancer Patients
Jun 12, 2014
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Molecular Partners (6ML0) have in its pipeline
6ML0 is currently developing the following drugs: Mp0533 (Multispecific Darpin Cd3 Engager Targeting Cd33, Cd123 And Cd70) Monotherapy, Part 1, Mp0533 (Multispecific Darpin Cd3 Engager Targeting Cd33, Cd123 And Cd70) Monotherapy, Part 2-Arm A, Mp0533 (Multispecific Darpin Cd3 Engager Targeting Cd33, Cd123 And Cd70) + Azacitidine + Venetoclax, Mp0533 With Obinutuzumab Pretreatment, Mp0533 + Azacitidine + Venetoclax With Optional Obinutuzumab Pretreatment, Arm B Relapsed/Refractory Aml, Mp0533 + Azacitidine + Venetoclax With Optional Obinutuzumab Pretreatment, Arm B In Treatment Naïve Patients, Mp0317, A Tri-Specific Fibroblast Activation Protein (Fap) X Cd40 Darpin® Drug Candidate (Q3w Regimen), Mp0317, A Tri-Specific Fibroblast Activation Protein (Fap) X Cd40 Darpin® Drug Candidate (Q1w Regimen), Ensovibep. These drug candidates are in various stages of clinical development as the company works toward FDA approval.